Ten healthy volunteers (six males; four females) completed this double-blind, crossover design study of vigabatrin vs placebo. Subjects were tested on four oscasions; at the baselines of the placebo and the vigabatrin phase, and two weeks thereafter. At time of testing, the dose of vigabatrin was 2 g daily. Changes in cognition were assessed using the Sternberg, the PASAT, the Stroop, and Critical Fusion Flicker tests. Mood was assessed with the Mood Adjective Check List, the Beck Depression Inventory, and the Irritability, Depression and Anxiety scales. We found one drug, and one placebo, related significant difference on a measure of cognition.
INTRODUCTION
Vigabatrin is one of the new antiepileptic drugs (AEDs) with a novel mode of action. It is known to inhibit GABA transaminase and reliably to increase GABA levels in the central nervous system'.
It is known that anticonvulsant drugs can affect cognitive function*. In general, all of the standard AEDs have been shown to affect some aspect of cognition in patients with epilepsy, although there is some debate about the relative contribution of the different compounds3.
Of the new agents, vigabatrin has been the most studied. Our group has carried out two previous studies of the effects of vigabatrin on various cognitive tests when given as add-on therapy to patients. McGuire et al4 used a computerised battery of attention and concentration tasks, while Dijkstra et al5 selected essentially non-motor tasks. Neither study showed any detrimental effect of vigabatrin, and in each study, patient performance actually improved on one of the selected tasks. Other groups have also investigated the cognitive effects of vigabatrin in patients. Dodrill et af6 on a completely different test regime based largely on the Halstead-Reitan battery, noted no effects. Grunewald et af' found 1059-l 311/96/030205 + 04 $12.0010 a small but significant impairment on only one of their cognitive tasks.
A major problem of interpreting these studies relates to the effects of the drug on epilepsy variables. Vigabatrin is a powerful anticonvulsant rendering up to 10% of patients seizure free'. Such changes can influence cognition. Studies of volunteers are therefore helpful in interpreting the data which is collected in clinical investigations. We have previously carried out volunteer studies on a number of AEDs9-". It is possible, in a controlled environment, to carry out doubleblind placebo investigations and interpret the results without having to consider extraneous illness variables. We present here the results of a volunteer study with vigabatrin.
MATERIALS AND METHODS
Eleven healthy volunteers were recruited to a double-blind crossover trial of vigabatrin vs. placebo. All met the exclusion criteria, having no current or past neurological or psychiatric problems. One dropped out during the vigabatrin phase because of the development of a skin problem, considered unrelated to vigabatrin.
The ten subjects who completed the study 0 1996 British Epilepsy Association included six males and four females with a mean age of 31.5 years. They were randomly allocated to two treatment groups. Group 1 (GVG/Plac) received active drug for two weeks. After a minimum one week washout phase, they were then given placebo matched tablets for a further two weeks. Group 2 (Plac/GVG) were treated in reverse order to Group 1. Vigabatrin was prescribed at 1 g, increasing after one week, to 2 g daily.
Subjects were tested on four occasions; at the beginning and end of each of the two treatment phases. Cognition and mood were measured with tests detailed below.
The Paced Auditory Serial Addition Task (PASAT)
An audio-taped presentation of numbers is given at a set pace. Subjects have to add each digit to the one preceding it and answer aloud before the next number is presented. There are three different paces (2.0,1.6 and 1.2 seconds) and each presentation contains 50 number items. Scores are obtained by calculating the correct number of additions made for each presentation.
It is a measure of information processing12.
scores are obtained for correct and corrected answers. This test examines the competing demands for attention that one set of stimuli has on another, and requires concentration with an ability to suppress unwanted information14.
The Sternberg
A computer-generated series of digits is presented sequentially and momentarily on screen. It is followed by a target number. Subjects have to identify whether the target number was present in the preceding series. Each series varies between two and six numbers. There are 60 presentations, Latency is measured in time taken to complete the task (l/6 seconds) and total scores are obtained by calculating the number of correct identifications.
This is a memory scanning and attention task15. Using the 'up' mode of the portable Leeds Psychomotor tester, four LEDs flicker at an increasing speed (cycles per second). Subjects have to respond when the lights appear to be stationary. In the 'down' mode, the apparently stationary lights flicker at a decreasing speed and subjects have to respond when the lights first appear to flicker. Six presentations are made in each mode, which are repeated once, to give two modal score totals. These are added together to give a total score. It is a task of central integrating ability, known to be sensitive to sedative and stimulant effects13.
The Stroop colour-word task This is a two task test. Firstly, subjects are asked to read a list of colour words (printed in incongruent ink) in two minutes. In the second task, they are asked to name the ink colour, which is incongruent with the actual colour word. Latency is measured as time taken to complete each task, (with a cut off at 120 seconds), whilst This l&item questionnaire yields a total score for depression.
Statistical analysis of a crossover trial design requires that before treatment effects can be compared, period effects and treatment-period interaction effects are investigated".
This was done by f-tests, comparing the differences between periods in the two groups (a period effect), and the average scores of the two treatments in the order that they were given (a treatmentperiod interaction effect). Paired r-tests were then applied to make treatment comparisons. RESULTS t-tests revealed significant treatment differences between baseline and vigabatrin scores on the 1.6 seconds PASAT (P = 0.004), as well as between baseline and placebo scores on the 1.2 seconds PASAT (P = 0.008).
There was a significant period effect on the Stroop colour-word score (P = 0.03), the 2.0 seconds PASAT (P = O.OS), and the Sternberg latency (P = 0.01). In addition, treatment-period interaction effects were noted on the MACL vigour (P =0.03) and the IDA hostility (P = 0.02) (see Table 1 ).
DISCUSSION
The data supports the clinical studies which suggest that vigabatrin has minimal or no adverse consequences for some aspects of cognition. In this study we noticed a significant improvement with vigabatrin, on the 1.6 second PASAT test. This was interesting because in our patient tria15, we had reported improvements on this test at 1.2 seconds, whilst in this study, there was a significant placebo effect at this speed. The data suggests that these may be chance effects.
The essentially negative results (see Table l ), may have been related to a time factor; we were only giving vigabatrin for 14 days, and our patient studies were done at 28 days. It is possible that psychotropic effects emerge thereafter. However, the biochemical effects of vigabatrin clearly emerge within a few days of starting treatment', and in a sub-group of patients in whom behavioural problems emerged following treatment with vigabatrin, effects were reported in some patients, following a few doses (Thomas er al unpubl. res.). Alternatively, the beneficial effects on cognition in patients with epilepsy, may have been related to improved cerebral function, also reflected in diminishing seizure frequency in some patients in those studies.
The test battery we selected for the volunteer studies was one that we had earlier used in one of the patient studies' which was composed of tests with minimal motor effects and examined some components of higher cognitive function, particularly attention and concentration.
These tests have been shown to be susceptible to the influence of anticonvulsant drugs'," (Kendrick er al unpubl. res.). It is possible that with the use of other tests, some changes may have been detected, but the results as presented here are in keeping with the accumulating data on vigabatrin and cognitive function, namely that of all of the anticonvulsant drugs that have been examined so far, it appears to have no obvious adverse effect8.
It could be argued that the small sample size of our study provides low statistical power to detect change. We were constrained by ethical considerations to examine our data on ten patients, and our essentially negative findings did not lead us to believe that increasing our sample size would have revealed meaningful significant differences. Furthermore, the dose of 2g was considered a reasonable equivalent to clinical practice, and so we did not subject volunteers to higher doses. We assessed mood with standardized questionnaires which we have used previously in patients with epilepsy. No significant differences emerged; again similar to the data collected in our clinical studies4.5. Although a sub-group of patients who develop mood disorders with vigabatrin has been described2'*22, these data suggest that for the majority of people taking the drug, alteration of mood is not a significant problem.
We observed no treatment period interaction effects on cognitive tasks, reflecting either the adequacy of the trial design or supporting the data of the lack of effects of vigabatrin on cognitive function. Period effects were noted for some of the tasks, essentially reflecting a practice effect. These are commonly encountered in psychological studies with this design and emphasise the necessity to continue to develop practice free tasks.
